Loading stock data…
Replimune Group, Inc. (REPL)
$11.20-0.43 (-3.70%)
After Hours$11.20+0.00 (+0.00%)· Last close Jun 29
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Replimune Group, Inc. in the Healthcare sector is trading at $11.20 with a market capitalization of $824M. Wall Street consensus targets $7.67 (6 analysts), implying a -31.5% move over the next 12 months. The stock is currently near its 52-week high of $13.24, remaining 55.3% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -31.5% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$71.53M↑ | -$83.91M↑ | -$90.00M↓ | -$78.78M↓ | -$65.64M |
| Net Income | -$70.93M↑ | -$83.10M↑ | -$86.69M↓ | -$74.13M↓ | -$66.34M |
Peer Comparison
JNJUNHPFE
Fundamentals
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intend...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$824.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-149.55%
Volume
Today's trading volume
3.71M
Recent News
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s. Previous close: $26.99. An 81% gain, overnight. Read that last number again. This stock nearly doubled in a single session. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Now, I could just tell you “wow, what a move” and carry on with my day. But that’s not what I do, and it’s not wh
Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
Biotech stocks climbed Wednesday after the Food and Drug Administration signaled the end of a "nail-biting journey" for UniQure.
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.
Why Is REPL Stock Gaining In Pre-Market Today?
Replimune shares gained ahead of its fourth-quarter earnings report, following positive human-trial data of its immunotherapy RP2.
How Replimune’s Drug Got Third Chance After White House Intervention
Company representatives met with officials in early May and by month’s end, the FDA was planning to review the melanoma medication again.